Age-related cognitive decline, mild cognitive impairment, and progression to other Alzheimer’s Disease-related dementias affects the well-being of older adults, their families and caregivers.
Sixteen million individuals in the US are living with mild cognitive impairment, a precursor to Alzheimer’s Disease.
The total cost of health care and long-term care-related payments in 2020 for all individuals with dementia was estimated at $305 billion.
There are currently no pharmacologic solutions and no other treatments with strong evidence for the prevention of age-related cognitive decline, mild cognitive impairment, or progression to clinical Alzheimer’s-type dementia.